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3T3 cells null for the type 1 insulin-like growth factor
receptor are refractory to stimulation by a variety of
purified growth factors that are known to be required
for the stimulation of other 3T3 cells. However, these
cells, known as R2 cells, grow in serum-supplemented
medium and also in media conditioned by certain cell
lines. We report here the purification of a growth factor
that stimulates DNA synthesis (and growth) of R2 cells.
The growth factor, purified to homogeneity by SDS-
polyacrylamide gel electrophoresis, was identified as
the granulin/epithelin precursor by an accurate deter-
mination of the masses of endoproteinase Lys-C pep-
tides using matrix-assisted laser desorption ionization
mass spectrometry, followed by a data base search. The
granulin/epithelin precursor is a little known growth
factor, secreted by a variety of epithelial and hemopoi-
etic cells. It is at present the only purified growth factor
that can stimulate the growth of mouse embryo fibro-
blasts null for the type 1 insulin-like growth factor
receptor.
It has been known for several years that the insulin-like
growth factors (IGF-I and -II)1 play a central role in the growth
of cells in culture (reviewed in Ref. 1). Most cells in the animal
body have type 1 IGF receptors (IGF-IR) and require the acti-
vation of this receptor by its ligands for optimal growth, both in
vivo (2, 3) and in vitro (reviewed in Ref. 4). The requirement for
IGF-I is especially evident with mouse and human fibroblasts,
where it combines with other growth factors (for instance,
platelet-derived growth factor) in stimulating growth of cells
under defined conditions (serum-free medium). Singly, these
growth factors cannot stimulate the growth of normal fibro-
blasts, like 3T3 cells (5). R2 cells (6, 7) are 3T3 fibroblasts that
originated from mouse embryos with a targeted disruption of
the IGF-IR genes (2, 3). R2 cells have been extensively used in
the past years to study the role of the IGF-IR in mitogenesis,
transformation, and apoptosis (see the editorial in Ref. 8). R2
cells do not grow in serum-free medium supplemented with the
growth factors that are known to sustain the growth of other
3T3 cells, with a physiological number of IGF-IRs (1). Singly or
in combination, the following growth factors failed to stimulate
the growth of R2 cells: platelet-derived growth factor, epider-
mal growth factor, IGF-I and II, insulin, basic and acidic fibro-
blast growth factor, TGFa, TGFb, and hepatocyte growth factor
(7, 9, 10). In fact, even R2 cells overexpressing either the
epidermal growth factor receptor (11) or the platelet-derived
growth factor b receptor (12) are unresponsive to their respec-
tive growth factors, indicating a central role of the IGF-IR in
fibroblast growth. Reintroduction of a wild type IGF-IR
promptly restores the growth deficits of R2 cells (6, 7). How-
ever, the fact that R2 cells grow in 10% serum clearly indicates
that serum contains one or more growth factors that bypass the
requirement for IGFs. R2 cells also grow in medium condi-
tioned by certain (but not all) cell lines (9). In previous papers
(9, 13), we reported that the conditioned medium of BRL-3A
cells stimulated the growth of R2 cells. The partial fraction-
ation of a growth-stimulating polypeptide derived from
BRL-3A cells was reported by Xu et al. (9). The growth factor
has now been identified as the granulin/epithelin precursor
(14–16) by high accuracy peptide mass mapping with matrix-
assisted laser desorption ionization (MALDI) mass spectrome-
try (MS), followed by data base searching with a set of meas-
ured peptide masses. Further evidence for its identity was
provided by sequence analysis of a peptide by Edman degrada-
tion after purification by reverse phase chromatography. Given
the central role of the activated IGF-IR in the growth of cells in
vivo and in vitro (see above), the identification of the granulin/
epithelin precursor as a growth factor that bypasses the re-
quirement for IGFs can be of considerable interest to the many
investigators in the field of IGFs and IGF-binding proteins and
of cell proliferation in general.
EXPERIMENTAL PROCEDURES
Cell Lines and Culture Conditions—All experiments used as the test
cell line R2 cells (6, 7), which are 3T3-like cells derived from mouse
embryos with a targeted disruption of the IGF-IR genes (2, 3). These
cells have been repeatedly described and characterized in previous
papers from this laboratory (11). They grow in 10% fetal bovine serum,
but they do not grow at all in serum-free medium supplemented with
purified growth factors. R2 cells were maintained routinely in Dulbec-
co’s modified Eagle’s medium containing 10% fetal bovine serum.
For the production of conditioned medium, BRL-3A cell line was
chosen after a primary screening of several different cell lines for their
ability to secrete a growth stimulating activity into serum-free medium
(9). BRL-3A is a cell line originated as a clone from a 5-week-old female
Buffalo rat liver (Life Technologies, Inc.). Serum-free medium condi-
tioned by the BRL-3A cells produces a family of polypeptides, including
a multiplication-stimulating activity that was reported to be related to
somatomedins and stimulate [3H]thymidine incorporation into DNA in
chick embryo fibroblasts and human skin fibroblasts (17). BRL-3A cells
were maintained in F-10 medium plus 10% fetal bovine serum.
Preparation of Conditioned Medium—Conditioned medium from
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BRL-3A cells was prepared as described in detail by Xu et al. (9).
Collected medium was sterilized using a 0.2-mm filter and stored frozen
at 220 °C until needed.
DNA Synthesis—R2 cells were seeded at a density of 5 3 103/cm2 on
coverslips in Dulbecco’s modified Eagle’s medium containing 10% fetal
bovine serum and allowed to attach for 24 h. The cultures were then
made quiescent for 96 h in serum-free medium prior to the addition of
growth factors or conditioned medium. Tritiated thymidine (0.5 mCi/ml)
was added at the same time as growth factors or conditioned medium,
and the incubations were continued for 24 h. The cells were then fixed
in cold methanol and autoradiographed by standard procedures. The
percentage of labeled cells was determined by scoring a total of 1,000
cells. DNA synthesis stimulating activity was expressed as the percent-
age of labeled nuclei.
Chromatography Procedures—The purification of the growth factor
is schematically represented in Fig. 1.
Polyacrylamide Electrophoresis—Polyacrylamide electrophoresis of
proteins in any sample was performed using Precast Ready Gels and
Mini-Protean II cell system (Bio-Rad) unless otherwise noted. 4–20%
linear gradient Tris-glycine gels were used for the inset of Figs. 2 and
for Fig. 3B, whereas 4–15% linear gradient Tris-glycine gels were used
for Fig. 3A and the inset of Fig. 4.
Recovery of Protein Resolved under Nonreducing Condition—200 ml
of fraction 38 (about 3 mg of protein) from the reverse phase chroma-
tography procedure was lyophilized by Speed-Vac concentrator and
resolved by polyacrylamide gel electrophoresis under nonreducing con-
dition. One-sixth of the sample was run onto a separate lane for silver
stain as reference. Slices above, below, and corresponding to the desired
band detected by silver stain (Fig. 3B) were cut out from the gel and
were incubated in 1 ml of phosphate-buffered saline at 4 °C for 12 h.
The supernatant was dialyzed by Slide-A-Lyzer 10K Dialysis Cassettes
(Pierce) twice against saline for 6 h and twice against distilled water for
6 h (18). The product was concentrated by Centricon-10 (Amicon, mo-
lecular weight cut-off of 10,000) unit; four-fifths were tested for the
ability to stimulate DNA synthesis, and one-fifth was analyzed by
SDS-PAGE under reducing conditions (Fig. 4).
Renaturation of Protein Reduced by SDS-PAGE—Target protein (3
mg) in 200 ml of fraction 38 from reverse phase chromatography proce-
dure was also studied by cutting out the desired band from the gel after
resolution by SDS-PAGE. The protein was eluted from the gel band,
renatured, and characterized, basically according to the method of
Hager and co-workers (19, 20) and Ishii et al. (21).
Preparation of Protein for Peptide Analysis—To obtain a homogenous
protein preparation for peptide analysis, the active factor was purified
by SDS-PAGE. The preparation was lyophilized in a vacuum concen-
trator, and the protein were subjected to reduction by dithiothreitol and
cysteine alkylation by 4-vinylpyridine in Laemmli SDS-PAGE sample
buffer. The mixture was applied to a single lane of a 14% Novex precast
Tris-glycine gel and subjected to electrophoresis under normal condi-
tions. The protein was visualized by Coomassie Blue stain, the major
component was excised, and the gel slice was destained in preparation
for endoproteinase digestion in situ (22).
Protein Digestion, Peptide Isolation, and Sequence Analysis—The
protein present in the gel slice was subjected to endoproteinase Lys-C
(Achromobacter lyticus from Wako) digestion for 16 h. Peptides were
extracted from the gel slice in organic solvents, and 10% of the mixture
was subjected to analysis by MALDI reflectron time-of-flight (MALDI-
TOF) MS. The bulk of the peptide mixture (90%) was subjected to
reverse phase capillary chromatography (Applied Biosystems 173A cLC
Microblotter system) with deposition of the peptides on a polyvinylidene
difluoride membrane after passage through the detector cell. One peak
in the chromatogram was subjected to Edman degradation using an
Applied Biosystems Procise 494 protein sequencer through direct intro-
duction of the polyvinylidene difluoride membrane and use of “blot”
cycles.
Protein Data Base Search with Peptide Mass Data—Peptide monoiso-
topic masses were used for protein data base searching using Pep-
tideSearch software2 running on an Apple Power Macintosh 7600/120.
IRS-1 and MAP Kinase Phosphorylation—Cells were treated as for
DNA synthesis (see above), and lysates were prepared from them for
IRS-1 and MAP kinase phosphorylation following techniques previously
described (10). For IRS-1, 300 mg of protein lysate were immunoprecipi-
tated overnight at 4 °C with anti-IRS-1 and protein A-agarose (Onco-
gene Science). After resolution on a 4–15% SDS-PAGE (Bio-Rad) and
transfer to a nitrocellulose filter, the membrane was probed with anti-
phosphotyrosine antibody (Transduction Laboratories). Detection was
carried out with ECL (Amersham Pharmacia Biotech). After membrane
incubation with stripping buffer (100 mM 2-mercaptoethanol, 2% SDS,
62.5 mM Tris-HCl, pH 7.6) at 50 °C for 30 m, membrane was washed
twice with TBS-T buffer (0.1 M Tris, 1.5 M NaCl, 0.5% Triton Y-100)
blocked overnight in 5% nonfat milk in TBS-T buffer and probed with
anti IRS-1 antibody (Oncogene Science). MAP kinase phosphorylation
was determined following the instructions of the antibody’s manufac-
turer (Promega).
RESULTS
Purification of the Growth Factor—In a previous paper (9),
we showed that R2 cells could grow in media conditioned by
three different cell lines, BRL-3A, T98G (a human glioblastoma
cell line), and T24H (a 3T3 cell line transformed by an activated
ras). Other cell lines were also tested and found to be negative,
i.e. their conditioned media did not elicit a response in R2 cells.
Among the other cell lines tested were two normal cell lines,
WI-38 human diploid fibroblasts and Balb/c 3T3 cells, and a
human breast cancer cell line, MCF-7. In general, the cells
whose conditioned media stimulated R2 cells were cell lines
capable of growing in serum-free medium, whereas the nega-
tive cell lines required IGF-I (as well as other growth factors)
for growth. We concentrated on BRL-3A conditioned medium,
because it seemed more potent than other conditioned media in
stimulating the growth of R2 cells. The partial purification of
the unidentified growth factor has been described by Xu et al.
(9). A diagram of the purification procedure is given in Fig. 1.
At every step, the various fractions were used to stimulate R2
cells. Although the activity was originally identified as capable
of causing an increase in cell number in R2 cells (9), in later
experiments, the usual procedure was to monitor each fraction
for the ability to stimulate DNA synthesis. This procedure is
easier and more sensitive than cell number, because even when
2 M. Mann (1996) peptide search software for Apple Macintosh comput-
ers (available via anonymous ftp at ftp:://mac-mannb.embl-heidelberg.
de/saturn/pub/software).
FIG. 1. Diagram of the purification procedure. The growth-pro-
moting activity was originally designated as BRL-GF, for growth factor
from BRL-3A cells. It will be referred to, in the rest of the paper, as
granulin/epithelin.

























close to 100% of cells enter S phase, the increase in cell number
is only a doubling. However, the purified growth factor can also
stimulate cell growth, in addition to stimulating DNA synthe-
sis. A pool of fractions from the phenyl-Sepharose column that
was active in stimulating the growth of R2 cells was further
fractionated by reverse phase chromatography (Fig. 2). The
highest stimulating activity was found in fractions 38–40.
When these fractions were run on a gel, a single band was
found at approximately 60–65 kDa (inset of Fig. 2). This band
was eluted (see “Experimental Procedures”) and rerun again on
a gel (Fig. 3), both under denaturing and nondenaturing con-
ditions. Again, only one band was detectable on silver-stained
gels.
These bands were again eluted and tested for their ability to
stimulate DNA synthesis in R2 cells in serum-free medium and
for peptide analysis. Fig. 4 shows that the protein from the
nondenatured gel of Fig. 3, was capable of inducing DNA syn-
thesis in R2 cells, to an extent (about 70% of cells) only a little
inferior to 10% serum (80%). The band eluted from the dena-
turing gel was essentially inactive, as were the eluates from
regions above or below the active band. The remaining material
was again loaded on gels, and the inset of Fig. 4 shows the
bands (much decreased in intensity) at the same location as in
the previous figures.
Identification of the Growth Factor as the Granulin/Epithe-
lin Precursor—The active fraction was subjected to a number of
analyses, as described under “Experimental Procedures.” An
aliquot of the protein preparation was analyzed by direct Ed-
man degradation, because analysis by SDS-PAGE suggested a
purity level of 95% for the growth factor; however, no sequence
information was obtained (an indication of protein blockage). A
new and rapid method for the identification of proteins in-
volved high accuracy peptide mass mapping using delayed ion
extraction MALDI time-of-flight-TOF MS, followed by protein
data base searching with the peptide masses (24). The protein
band shown in Fig. 3 was digested with endoproteinase Lys-C,
and an aliquot of the peptide mixture was used to determine
the accurate molecular masses (generally ,30 parts/million) by
delayed ion extraction MALDI-TOF MS. The molecular masses
of the peptides were used to search an in-house nondegenerate
protein data base, and the protein was identified as the rat
granulin/epithelin precursor. Table I compares the regions of
the epithelin/granulin precursor identified by delayed ion ex-
traction MALDI reflectron TOF MS with the mouse protein and
human protein, both predicted from their respective cDNA. The
sequences obtained by us showed 100% homology with the rat
granulin/epithelin, 87% homology to the mouse protein, and
72% homology to the human protein. The growth factor, it
should be noted, was purified from BRL-3A cells that are of rat
origin. The sequences obtained from our band cover 179 of 589
amino acids or 30.4% of the rat granulin precursor. It seems
reasonable to conclude that at least one of the growth factors in
the BRL-3A conditioned medium that stimulates the growth of
R2 cells is the granulin/epithelin precursor.
IRS-1 and MAP Kinase Activation—We have conducted pre-
liminary experiments on the possible pathways used by the
granulin/epithelin precursor to induce DNA synthesis in R2
cells. To circumscribe the problem, we have investigated the
activation (tyrosyl phosphorylation) of IRS-1 as well as MAP
kinase activation by the granulin/epithelin precursor, following
the same procedures outlined above. These experiments are
shown in Fig. 5 (A, B, and C). IRS-1 tyrosyl phosphorylation is
not increased by stimulation with the granulin/epithelin pre-
cursor (Fig. 5A). There is a faint band of phosphorylated IRS-1,
but this is present also in unstimulated cells. We have already
noticed before a slight activation of IRS-1 in cells attached to
the substratum (10, 11), probably because of the known inter-
action of IRS-1 with other cellular components. Fig. 5B shows
the levels of IRS-1 protein in the immunoprecipitates. We con-
clude that stimulation with the granulin/epithelin precursor
FIG. 2. Last step in the purification
procedure. The active fractions from the
phenyl-Sepharose column were pooled
and fractionated by reverse phase chro-
matography. Solid line with crossed cir-
cle: protein amounts. Dashed line with
open circle, activity in stimulating DNA
synthesis in R2 cells. Inset, gel of the most
active fractions, showing a strongly visi-
ble single band in fractions 38, 39, and 40.
FIG. 3. Purity of the growth factor. Only fraction 38 of the previ-
ous figure was used. By silver staining, a single band was visible on



























has no effect on tyrosyl phosphorylation levels of IRS-1. This is
not the case with MAP kinases, which are sharply activated by
the granulin/epithelin precursor (Fig. 5C), indicating that this
growth factor eventually connects with the MAP kinase path-
way in stimulating DNA synthesis.
DISCUSSION
We have purified, partially sequenced, and identified a
polypeptide from BRL-3A conditioned medium that stimulates
DNA synthesis (and growth in number) of R2 cells that are null
for the IGF-IR (6, 7). This growth factor has been identified as
the granulin/epithelin precursor (14–16). The identification of
the granulin/epithelin precursor as a growth factor that by-
passes the requirement for a functional IGF-IR is of consider-
able interest for several reasons: 1) The IGF-IR plays a major
role in the growth of cells, both in vivo and in vitro (see Intro-
duction), but clearly its requirement is not an absolute one,
because it can be circumvented by a single purified growth
factor. 2) Although epithelins are produced also by normal
tissues (see below), in cells in culture they are predominantly
expressed by transformed cell lines that can grow in serum-free
medium. This raises the question whether the expression of
epithelins may also be involved in transformation. 3) The
IGF-IR shares with other growth factor receptors the main
mitogenic pathway (commonly referred to as the ras pathway).
However, the discovery of a purified growth factor that by-
passes this pathway opens the possibility of identifying a new
mitogenic pathway that is presumably ras-independent (7). 4)
One can also predict the usefulness of the granulin/epithelin
precursor in studies dealing with the inhibitory action of IGF-
binding proteins, because stimulation of cell proliferation could
be achieved in the absence of IGFs.
Epithelins were originally purified from rat kidney as two
small single chain peptides (approximately 6 kDa) containing
about 20% cysteine (14). Epithelin1 stimulated the prolifera-
tion of murine keratinocytes, whereas epithelin2 had inhibitory
potential (14, 25). At about the same time, the same peptides
were isolated from leukocytes and termed granulins (26). Sub-
sequently, Bhandari et al. (15) cloned the granulin precursor
cDNA and reported that the prepropeptide of the human
granulins is a 593-residue glycoprotein containing seven tan-
dem repeats of the 12-cysteine granulin domain. The human
granulin/epithelin gene codes for at least four small epithelin
peptides (27). In addition to granulin A and B, an additional
peptide, granulin F, which had never been isolated before but
whose primary structure is known on the basis of the cDNA
sequence, was isolated from human urine (28). The rat granu-
lin precursor codes for 589 amino acid residues (BRL-3A cells
are from rat liver) and is 72% homologous to the human granu-
lin precursor and 87% homologous to the mouse granulin pre-
cursor (16, 25). The primary structure of the epithelins has
been reported by Belcourt et al. (29). It has also been reported
that the granulin/epithelin protein motif has an unusual struc-
ture consisting of a parallel stack of b-hairpins stapled together
by six disulfide bonds (30). The granulin gene has an unusual
genomic structure containing 12 exons interrupted by 11 in-
trons mapped to chromosome 17 in human and 13 exons inter-
rupted by 12 introns mapped to chromosome 11 in mouse,
respectively (15, 31, 32). A putative promoter has also been
characterized at the 59 end of the granulin gene (33). The
granulin gene is conserved widely in species, suggesting a
possibly widespread growth regulatory function (30).
Although granulin/epithelins have been usually tested as the
small peptides, Zhou et al. (34) purified the precursor protein
and showed that it was, by itself, a mitogen for cells in culture.
We are now showing that the granulin/epithelin precursor is
mitogenic per se, in fact that it can stimulate DNA synthesis
(and growth, see Ref. 9) in serum-free medium in R2 cells that
are known to be refractory to stimulation by other purified
growth factors, singly or in combination. Interestingly, Zhou et
al. (34) purified the granulin/epithelin precursor from an “in-
sulin-independent” cell line. Because insulin in tissue cultures
is generally used at concentrations that activate the IGF-IR
(35), their observation is an indirect confirmation of our obser-
vation that the granulin/epithelin precursor bypasses the re-
quirement for the IGF-IR. The stimulatory activity of the pre-
cursor, in respect to the small epithelins, may be due to the fact
that the small epithelins are a mixture of stimulatory and
inhibitory peptides (14, 25).
Our active polypeptide was inactivated by a denaturing gel.
This was not surprising, given the large number of cysteine
residues in the sequence (see above); furthermore, structural
evidence indicated the importance of proper formation of intra-
chain disulfide bonds of the granulin/epithelin (30). Finally,
epithelin-binding sites have been found in human breast car-
cinoma cells (36), but to our knowledge, no further information
on a putative receptor has been made available. A 170–175-
kDa protein has been reported (37) that binds the epithelial-
type transforming growth factor (TGFe), and this growth factor
is partially homologous to, but distinct from, the granulin/
epithelins (33, 38). This TGFe-specific receptor with a size of
approximately 170–175 kDa (37) is presumably different from
the putative receptor for granulin/epithelin, a membrane pro-
tein of 140–145 kDa (36).
It is worth mentioning that SDS-PAGE of proteins in frac-
tions 34 and 35 corresponding to the first active peak in Fig. 2
showed a single band of about 25–28 kDa by silver stain (data
not shown). Whether it is a TGFe or a processed granulin/
epithelin or another factor remains to be established. BRL-3A
conditioned medium is rich in growth-stimulating activities
(39–41), including IGF-II, originally identified as multiplica-
tion stimulating activity (17). IGF-II, however, cannot stimu-
late DNA synthesis in R2 cells, even at concentrations up to
200 ng/ml (10), and, in addition, the size of IGF-II is much
smaller than the size of the growth factor we have purified. It
FIG. 4. Activity of the bands of Fig. 3. The bands of Fig. 3 were
eluted and used for two purposes: 1) stimulation of DNA synthesis in R2
cells and 2) sequencing. DNA synthesis was determined as described
under “Experimental Procedures.” The sequences are given in Table I.
O, original sample; N, nondenatured sample; DR, denatured sample. U
and M are slices of gels immediately above or below the silver-stained
bands. The ordinate gives the percentage of labeled cells. Inset, gels of
the material left over. SFM, serum-free medium.

























is likely that there are other growth factors in the BRL-3A
conditioned medium that can stimulate growth of R2 cells. The
one we have purified and identified is the granulin/epithelin
precursor.
The identification of the granulin/epithelin precursor as a
growth factor that bypasses the requirement for an activated
IGF-IR is, in our opinion, important, both from a basic and an
applied point of view (see above). The IGF-IR is found in many
cell types and, as mentioned in the Introduction, is necessary
for the optimal growth of cells in vivo and in vitro. Further-
more, down-regulation of the IGF-IR causes massive apoptosis
of tumor cells in vivo, whereas overexpression causes transfor-
mation and protection from apoptosis (reviewed in Ref. 4). The
granulin/epithelin family could then become a target in those
tumor cells that have escaped regulation by the IGF-IR. At a
more basic level, our finding raises some interesting questions,
for instance, whether the granulin/epithelin peptides use and,
so to speak, usurp the IGF-IR signaling pathway(s), or whether
they induce mitogenicity (and/or transformation) by a totally
different pathway. This problem is being actively investigated,
but our preliminary results shown in Fig. 5 clearly indicate
that MAP kinases are activated, but IRS-1 is not. Thus, the
pathway stimulated by the granulin/epithelin precursor does
not seem to be dependent on IRS-1 and is therefore different
from the IGF-IR mitogenic pathway, which is heavily depend-
ent on IRS-1 (reviewed in Ref. 4). On the other hand, this
pathway connects again with one of the main pathways for
stimulation of DNA synthesis, which passes through the MAP
kinases. A considerable amount of evidence has accumulated,
indicating a crucial role of MAP kinases in the stimulation of
DNA synthesis by either growth factors or integrins or simply
attachment to the substratum (23, 42–45). Indeed, MAP kinase
activation has been reported to increase transcription from the
serum response element (45), which is usually correlated with
stimulation of DNA synthesis. Thus it seems that the granulin/
epithelin precursor bypasses the IRS-1 mitogenic pathway but
eventually joins the mitogenic pathway that is common to
many growth factors and mitogenic stimuli (23, 42–45). The
question now is where the granulin/epithelin pathway rein-
serts itself into the main mitogenic pathway, downstream from
IRS-1. At present, the only clue we have is that a plasmid
expressing the human granulin/epithelin precursor (courtesy of
Dr. Bateman) can make R2 cells grow in serum-free medium, a
property that, so far, is shared only by v-src (13). This finding
suggests that src may be involved in granulin/epithelin signal-
ing. The connection between c-src and MAP kinases has been
elucidated recently by Schlaepfer et al. (23), and the src path-
way may therefore be a prime candidate for further studies.
TABLE I
Sequence analysis of polypeptides from BRL-GF
r, rat; m, mouse; h, human; Grn, granulin; Epn, epithelin.



























FIG. 5. IRS-1 and MAP kinase activation by the granulin pre-
cursor. Stimulation of R2 cells and determination of IRS-1 phospho-
rylation and MAP kinase activation are described under “Experimental
Procedures.” A, IRS-1 tyrosyl phosphorylation at various times after
stimulation with the granulin precursor. The times are indicated above
the respective lanes. B, the same blot, stripped and stained for IRS-1. C,



























However, the complexities of the mitogenic signaling pathways
is such that several options must be kept open, especially in
view of the fact that no receptor for the granulin/epithelin
precursor has yet been cloned. The R2 cells expressing the
granulin/epithelin precursor are now being investigated in de-
tail for their growth phenotype, including transformation and
ability to protect cells from apoptosis and the ability to process
the precursor and their signaling potentials.
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Page 20082: Table I is incorrect. The corrected table is shown below.
TABLE I
Measured and calculated peptide masses for the Achromobacter Lys-C peptides from the rat
epithelin/granulin precursor (PIR2:B38128)
The table provides a list of the experimental molecular masses of the peptides found in the Lys-C digest of the growth factor in comparison with
the theoretical masses of the corresponding peptides of the granulin/epithelin precursor found in the data base file. The mass spectrum was
acquired on a Bruker Reflex instrument equipped with a delayed-extraction ion source. Calibrations were established with the use of an internal
peptide calibrant [ACTH-(18–39)] and a matrix ion (a-cyano-4-hydroxycinnamic acid). The sequence of one peptide (272–281) was established by
Edman degradation after isolation by capillary chromatography. MH1 refers to the monoisotopic mass of the protonated molecular ion.
Measured MH1 Calculated MH1 ppma Residue span Amino acid sequence from data base file
1075.609 1075.556 48 417–426 (K)GDRMVAGLEK(M)
1115.653 1115.609 39 272–281 (K)LPGYPVNEVK(C) b
1286.503 1286.500 1.5 408–416 (K)CMDEGYCQK(G)
1481.866 1481.857 6 346–359 (K)VTASLSLPDPQILK(N)
1623.656 1623.708 32 532–544 (K)DSQGGWACCPYVK(G)
1639.691 1639.763 43 496–511 (K)DAGSVQPSMDLTFGSK(V)
2012.806 2012.855 24 212–227 (K)TQCPDDSTCCELPTGK(Y)
2029.108 2029.170 30 573–589 (K)TPRWDILLRDPAPRPLL( )
2526.335 2526.307 10 190–211 (K)FPAQRTNRAVAFPFSVVCPDAK(T)
2654.390 2654.402 4 189–211 (K)KFPAQRTNRAVAFPFSVVCPDAK(T)
2674.259 2674.202 21 545–564 (K)GVCCRDGRHCCPIGFHCSAK(G)
3672.537 3672.585 13 282–309 (K)CDLEVSCPDGYTCCRLNTGAWGCCPFTK(A)
3973.792 3973.879 21 427–459 (K)MPVRQTTLLQHGDIGCDQHTSCPVGQTCCPSLK(G)
a Mass accuracy in parts per million (ppm).
b Identity confirmed by Edman degradation after isolation by capillary chromatography. Residues in parentheses are those which precede and
follow the Lys-C peptide in the precursor sequence.
The homology comparisons of the original Table I arise from the alignment of the data base sequences of the precursors from
the three species of organisms and do not relate to empirical sequence determinations. The peptide mass search of the data base
resulted in the identification of the growth factor as rat epithelin/granulin precursor, the sequence of which is 87% homologous
to the mouse precursor and 72% homologous to the human precursor. The growth factor was purified from BRL-3A cells of rat
origin. The peptide matches represent a sequence coverage of 30.4%, or 179 of the 589 amino acids in the precursor sequence, and
encompass the sequence from residues 189 to 589 (the C terminus).
We suggest that subscribers photocopy these corrections and insert the photocopies at the appropriate
places where the article to be corrected originally appeared. Authors are urged to introduce these
corrections into any reprints they distribute. Secondary (abstract) services are urged to carry notice of
these corrections as prominently as they carried the original abstracts.
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